top of page

"Many of my patients are not cured by a combination of surgery, and chemotherapy and radiation therapy. When current standard therapy fails my patients, we have to look to new approaches and new ways to solve the problem of brain cancer."

Cell Reports Medicine. 2024 Oct 15;5(10):101755.

De novo GTP synthesis is a targetable metabolic vulnerability in brain metastases.

Kieliszek AM, Mobilio D, Bassey-Archibong BI, Johnson JW, Piotrowski ML, de Araujo ED, Sedighi A, Aghaei N, Escudero L, Ang P, Gwynne WD, Zhang C, Quaile A, McKenna D, Subapanditha M, Tokar T, Shaikh MV, Zhai K, Chafe SC, Gunning PT, Montenegro-Burke JR, Venugopal C, Magolan J, Singh SK.

 

Nature Medicine. 2024 Aug 2;30:2936-2946.

Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR-T cells.

Chokshi CR, Shaikh MV, Brakel B, Rossotti MA, Tieu D, Maich W, Anand A, Chafe SC, Zhai K, Suk Y, Kieliszek AM, Miletic P, Mikolajewicz N, Chen D, McNicol JD, Chan K, Tong AHY, Kuhlmann L, Liu L, Alizada Z, Mobilio D, Tatari N, Savage N, Aghaei N, Grewal S, Puri A, Subapanditha M, McKenna D, Ignatchenko V, Salamoun JM, Kwiecien JM, Wipf P, Sharlow ER, Provias JP, Lu J-Q, Lazo JS, Kislinger T, Lu Y, Brown KR, Venugopal C, Henry KA, Moffat J, Singh SK.

Clinical Cancer Research. 2024 Feb 1;30(3):554-563.

Intratumoral Delivery of Chimeric Antigen Receptor-T Cells Targeting CD133 Effectively Treats Brain Metastases.

Kieliszek AM, Mobilio D, Upreti D, Bloemberg D, Escudero L, Kwiecien JM, Alizada Z, Zhai K, Ang P, Chafe SC, Vora P, Venugopal C, Singh SK.

Acta Neuropathologica. 2022 Dec;144(6):1127-1142.

The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers.

Tatari N, Khan S, Livingstone J, Zhai K, McKenna D, Ignatchenko V, Chokshi C, Gwynne WD, Singh M, Revill S, Mikolajewicz N, Zhu C, Chan J, Hawkins C, Lu J-Q, Provias JP, Ask K, Morrissy S, Brown S, Weiss T, Weller M, Han H, Greenspoon JN, Moffat J, Venugopal C, Boutros PC, Singh SK, Kislinger T.

Nature Communications. 2022 Dec 6;13(1):7506.

Characterization of an RNA binding protein interactome reveals the targetable post-transcriptional landscape of MYC-amplified medulloblastoma.

Kameda-Smith MM, Zhu H, Luo E-C, Suk Y, Xella A, Yee B, Chokshi C, Xing S, Tan F, Fox RG, Adile AA, Bakhshinyan D, Brown K, Gwynne WD, Subapanditha M, Miletic P, Picard D, Burns I, Moffat J, Paruch K, Fleming A, Hope K, Provias JP, Remke M, Lu Y, Reya T, Venugopal C, Reimand J, Wechsler-Reya RJ, Yeo GW, Singh SK.

Cancer Cell. 2022 Dec 12;40(12):1488-1502.e7.

Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma.

Gwynne WD, Suk Y, Custers S, Mikolajewicz N, Chan JK, Zador Z, Chafe SC, Zhai K, Escudero L, Zhang C, Zaslaver O, Chokshi C, Shaikh MV, Bakhshinyan D, Burns I, Chaudhry I, Nachmani O, Mobilio D, Maich WT, Mero P, Brown KR, Quaile AT, Venugopal C, Moffat J, Montenegro-Burke JR, Singh SK.

Cell Reports. 2022 Sep 27;40(13):111420.

Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma.

Qazi MA, Salim SK, Brown KR, Mikolajewicz N, Savage N, Han H, Subapanditha MK, Bakhshinyan D, Nixon A, Vora P, Desmond K, Chokshi C, Singh M, Khoo A, Macklin A, Khan S, Tatari N, Winegarden N, Richards L, Pugh T, Bock N, Mansouri A, Venugopal C, Kislinger T, Goyal S, Moffat J, Singh SK.

 

Journal for Immunotherapy of Cancer. 2022 Jan;10(1):e003289.

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.

Seyfrid M, Maich WT, Muhammad Shaikh V, Tatari N, Upreti D, Piyasena D, Subapanditha M, Savage N, McKenna D, Mikolajewicz N, Han H, Chokshi C, Kuhlmann L, Khoo A, Khalid Salim S, Archibong-Bassey B, Gwynne W, Brown K, Murtaza N, Bakhshinyan D, Vora P, Venugopal C, Moffat J, Kislinger T, Singh SK.

 

Science Advances. 2021 Dec 10;7(50):eabi5568.

Temporal profiling of therapy resistance in human medulloblastoma identifies novel targetable drivers of recurrence.

Bakhshinyan D, Adile AA, Liu J, Gwynne WD, Suk Y, Custers S, Burns I, Singh M, McFarlane N, Subapanditha MK, Qazi MA, Vora P, Kameda-Smith MM, Savage N, Desmond KL, Tatari N, Tran D, Seyfrid M, Hope K, Bock NA, Venugopal C, Bader GD, Singh SK.

 

Nature Communications. 2020 Aug 28;11: 4323.

Wnt activation is a therapeutic strategy in medulloblastoma.

Manoranjan B, Venugopal C, Bakhshinyan D, Adile AA, Richards L, Kameda-Smith MM, Whitley O, Dvorkin-Gheva A, Subapanditha M, Savage N, Tatari N, McKenna D, Bassey-Archibong B, Winegarden N, Hallett R, Provias JP, Yarascavitch B, Ajani O, Fleming A, Bader GD, Pugh TJ, Doble BW, Singh SK.

 

Cell Stem Cell. 2020 Jun 4;26(6):832-844.e6.

The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma.

Vora P, Venugopal C, Khalid Salim SK, Tatari N, Bakhshinyan D, Singh M, Seyfrid M, Upreti D, Rentas S, Wong N, Williams R, Ahmad Qazi M, Chokshi C, Ding A, Subapanditha M, Savage N, Mahendram S, Ford E, Adile AA, McKenna D, McFarlane N, Huynh V, Wylie RG, Pan J, Bramson J, Hope K, Moffat J 7, Singh SK.

 

Oncogene. 2020 Feb;39(7):1590-1599.

A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells.

Manoranjan B, Chokshi C, Venugopal C, Subapanditha M, Savage N, Tatari N, Provias JP, Murty NK, Moffat J, Doble BW, Singh SK.

Nature Medicine. 2019 Oct;25(10):1474-1476. 

Deciphering brain tumor heterogeneity, one cell at a time.

Qazi MA, Bakhshinyan D, Singh SK.

J Neurooncol. 2019 Jul;143(3):417-428

Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells.

Vora P, Seyfrid M, Venugopal C, Qazi MA, Salim S, Isserlin R, Subapanditha M, O'Farrell E, Mahendram S, Singh M, Bakhshinyan D, Chokshi C, McFarlane N, Dvorkin-Gheva A, Brown KR, Murty N, Moffat J, Bader GD, Singh SK.

Cancer Research. 2018 Sep 1;78(17):5023-5037.

Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.

Qazi MA, Vora P, Venugopal C, Adams J, Singh M, Hu A, Gorelik M, Subapanditha MK, Savage N, Yang J, Chokshi C, London M, Gont A, Bobrowski D, Grinshtein N, Brown KR, Murty NK, Nilvebrant J, Kaplan D, Moffat J, Sidhu S, Singh SK.

 

Cancer Res. 2018 Sep 1;78(17):5124-5134.

Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis.

Singh M, Venugopal C, Tokar T, McFarlane N, Subapanditha MK, Qazi M, Bakhshinyan D, Vora P, Murty NK, Jurisica I, Singh SK.

Springer. Sept 2018

Methods in Molecular Biology: Brain Tumour Stem Cells.

Textbook, Editors SK Singh and C Venugopal

Acta Neuropathol. 2017 Dec;134(6):923-940.

RNAi screen identifies essential regulators of human brain metastasis-initiating cells.

Singh M, Venugopal C, Tokar T, Brown KR, McFarlane N, Bakhshinyan D, Vijayakumar T, Manoranjan B, Mahendram S, Vora P, Qazi M, Dhillon M, Tong A, Durrer K, Murty N, Hallet R, Hassell JA, Kaplan DR, Cutz JC, Jurisica I, Moffat J, Singh SK.

Oncogene. 2017 Feb 2;36(5):606-617.

CD133+ brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence.

Garg N, Bakhshinyan D, Venugopal C, Mahendram S, Rosa DA, Vijayakumar T, Manoranjan B, Hallett R, McFarlane N, Delaney KH, Kwiecien JM, Arpin CC, Lai P-S, Gómez-Biagi RF, Ali AM, de Araujo ED, Ajani OA, Hassell JA, Gunning PT, Singh SK.

Clinical Cancer Research. 2015 Dec 1;21(23):5324-37.

Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.

Venugopal C, Hallett R, Vora P, Manoranjan B, Mahendram S, Qazi MA, McFarlane N, Subapanditha M, Nolte SM, Singh M, Bakhshinyan D, Garg N, Vijayakumar T, Lach B, Provias JP, Reddy K, Murty NK, Doble BW, Bhatia M, Hassell JA, Singh SK.

 

Stem Cells. 2013 Jul;31(7):1266-77.
FoxG1 interacts with Bmi1 to regulate self-renewal and tumorigenicity of medulloblastoma stem cells.

Manoranjan B, Wang X, Hallett RH, Venugopal C, Mack SC, McFarlane N, Nolte SM, Scheinemann K, Gunnarsson T, Hassell JA, Taylor MD, Lee C, Triscott J, Foster CM, Dunham C, Hawkins C, Dunn SE, Singh SK.

Stem Cell Research. 2012 Mar;8(2):141-53.

Bmi1 marks intermediate precursors during differentiation of human brain tumor initiating cells.

Venugopal C, Li N, Wang X, Manoranjan B, Hawkins C, Gunnarsson T, Hollenberg R, Klurfan P, Murty N, Kwiecien J, Farrokhyar F, Provias JP, Wynder C, Singh SK.

Nature. 2004 Nov 18;432(7015):396-401.

Identification of human brain tumour initiating cells.

Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB.

Cancer Res. 2003 Sep 15;63(18):5821-8.

Identification of a cancer stem cell in human brain tumors.

Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB.ri N, Provias JP, Murty NK, Moffat J, Doble BW, Singh SK.

Nature Medicine. 2019 Oct;25(10):1474-1476. 

Deciphering brain tumor heterogeneity, one cell at a time.

Qazi MA, Bakhshinyan D, Singh SK.

Select Publications

bottom of page